MolecularMD is acquired by ICON
21 févr. 2019 10h00 HE
|
MolecularMD
PORTLAND, Ore. and CAMBRIDGE, Mass., Feb. 21, 2019 (GLOBE NEWSWIRE) -- MolecularMD Corporation, a molecular diagnostic specialty laboratory that enables the development and commercialisation of...
Sysmex and MolecularMD Commence Global Partnership to Address the Challenges in Companion Diagnostics Development and Commercialization
28 nov. 2018 03h00 HE
|
MolecularMD
PORTLAND, Ore. and CAMBRIDGE, Mass., Nov. 28, 2018 (GLOBE NEWSWIRE) -- Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu), a Japanese in vitro diagnostics company, and...
First quantitative diagnostic test validated for Treatment-Free Remission for Eligible Patients with Ph+ CML-CP Treated with Tasigna® Cleared by Health Canada
13 nov. 2018 00h00 HE
|
MolecularMD
PORTLAND, Ore. and CAMBRIDGE, Mass., Nov. 13, 2018 (GLOBE NEWSWIRE) -- MolecularMD Corporation received regulatory approval from Health Canada for the MRDx® BCR-ABL Test, a quantitative diagnostic...
MolecularMD Launches Validated Tumor Mutation Burden Assay for Immuno-Oncology Clinical Trial Services
22 août 2018 05h00 HE
|
MolecularMD
PORTLAND, Ore., Aug. 22, 2018 (GLOBE NEWSWIRE) -- MolecularMD today announces it has validated Thermo Fisher Scientific’s Oncomine™ Tumor Mutation Load Assay for clinical research trials to aid...
MolecularMD and Genoptix Enter into a Definitive Agreement to Market the MRDx® BCR-ABL Test, a Companion Diagnostic for Treatment-free Remission in Ph+ CML-CP Patients Treated with Tasigna®
04 juin 2018 00h30 HE
|
MolecularMD
PORTLAND, Ore. and CARLSBAD, Calif., June 04, 2018 (GLOBE NEWSWIRE) -- MolecularMD Corporation and Genoptix, Inc. announced today that they have entered into an exclusive agreement to market and...
MolecularMD obtains FDA Authorization for the MRDx® BCR-ABL Test as a Companion Diagnostic for Treatment-Free Remission in Ph+ CML-CP Patients Treated with Tasigna
22 déc. 2017 18h02 HE
|
MolecularMD
PORTLAND, Ore. and CAMBRIDGE, Mass., Dec. 22, 2017 (GLOBE NEWSWIRE) -- MolecularMD Corporation, a diagnostics company that enables the development and commercialization of precision medicines in...
MolecularMD to Implement Promega’s Microsatellite Instability (MSI) Technology for Immuno-Oncology Applications
13 nov. 2017 20h00 HE
|
MolecularMD
PORTLAND, Ore. and CAMBRIDGE, Mass., Nov. 13, 2017 (GLOBE NEWSWIRE) -- MolecularMD announces that it has now become a Preferred Provider of Promega’s Microsatellite Instability (MSI) v1.2 Analysis...
MolecularMD Announces Partnership with Indica Labs to Support Improved Clinical Trial Histopathology Workflows Integrating Digital Biomarker Analysis Services
28 sept. 2017 20h00 HE
|
MolecularMD
PORTLAND, Ore. and CAMBRIDGE, Mass., Sept. 28, 2017 (GLOBE NEWSWIRE) -- MolecularMD, a provider of molecular and tissue-based clinical trial assays and diagnostics for oncology based drug...
MolecularMD achieves status as an ArcherDX Certified Service Provider and expands offering of novel NGS chemistries
01 juin 2017 05h00 HE
|
MolecularMD
PORTLAND, OR and CAMBRIDGE, MA--(Marketwired - June 01, 2017) - MolecularMD Corp., a molecular diagnostics company that provides clinical trial services and development of companion diagnostics for...
Asterand Bioscience and MolecularMD announce a partnership to accelerate targeted therapeutic biomarker validation, optimization, development and commercialization
15 févr. 2017 10h00 HE
|
MolecularMD
PORTLAND, OR and CAMBRIDGE, MA and DETROIT, MI--(Marketwired - February 15, 2017) - Asterand Bioscience, the leader in high quality, well-characterized human tissue and human tissue-based research...